- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.75 Å
- Oligo State
- hetero-4-4-mer
- Ligands
- 4 x MTA: 5'-DEOXY-5'-METHYLTHIOADENOSINE(Non-covalent)
- 4 x 01: N-(6-amino-5-cyclopropylpyridin-3-yl)-2-[(2R,5S)-2-(1,3-benzothiazol-5-yl)-5-methylpiperidin-1-yl]-2-oxoacetamide
01.2: 15 residues within 4Å:- Chain A: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, S.447, E.452, V.511, S.586, W.587, F.588
- Ligands: MTA.1
13 PLIP interactions:13 interactions with chain A- Hydrophobic interactions: A:L.320, A:L.320, A:V.334, A:F.335, A:F.335, A:F.335, A:W.587, A:F.588
- Hydrogen bonds: A:E.443, A:S.586, A:F.588
- Water bridges: A:Q.317, A:S.447
01.26: 15 residues within 4Å:- Chain C: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, S.447, E.452, V.511, S.586, W.587, F.588
- Ligands: MTA.25
13 PLIP interactions:13 interactions with chain C- Hydrophobic interactions: C:L.320, C:L.320, C:V.334, C:F.335, C:F.335, C:F.335, C:W.587, C:F.588
- Hydrogen bonds: C:E.443, C:S.586, C:F.588
- Water bridges: C:Q.317, C:S.447
01.50: 15 residues within 4Å:- Chain E: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, S.447, E.452, V.511, S.586, W.587, F.588
- Ligands: MTA.49
13 PLIP interactions:13 interactions with chain E- Hydrophobic interactions: E:L.320, E:L.320, E:V.334, E:F.335, E:F.335, E:F.335, E:W.587, E:F.588
- Hydrogen bonds: E:E.443, E:S.586, E:F.588
- Water bridges: E:Q.317, E:S.447
01.74: 15 residues within 4Å:- Chain G: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, S.447, E.452, V.511, S.586, W.587, F.588
- Ligands: MTA.73
13 PLIP interactions:13 interactions with chain G- Hydrophobic interactions: G:L.320, G:L.320, G:V.334, G:F.335, G:F.335, G:F.335, G:W.587, G:F.588
- Hydrogen bonds: G:E.443, G:S.586, G:F.588
- Water bridges: G:Q.317, G:S.447
- 16 x CL: CHLORIDE ION(Non-functional Binders)
CL.3: 2 residues within 4Å:- Chain A: Q.117
- Chain G: P.403
Ligand excluded by PLIPCL.4: 3 residues within 4Å:- Chain A: S.329
- Chain G: G.83, W.86
Ligand excluded by PLIPCL.5: 4 residues within 4Å:- Chain A: R.542, Y.543
- Chain C: R.109, E.112
Ligand excluded by PLIPCL.6: 4 residues within 4Å:- Chain A: Q.596, S.631, A.632, H.634
Ligand excluded by PLIPCL.27: 2 residues within 4Å:- Chain C: Q.117
- Chain E: P.403
Ligand excluded by PLIPCL.28: 3 residues within 4Å:- Chain C: S.329
- Chain E: G.83, W.86
Ligand excluded by PLIPCL.29: 4 residues within 4Å:- Chain A: R.109, E.112
- Chain C: R.542, Y.543
Ligand excluded by PLIPCL.30: 4 residues within 4Å:- Chain C: Q.596, S.631, A.632, H.634
Ligand excluded by PLIPCL.51: 2 residues within 4Å:- Chain C: P.403
- Chain E: Q.117
Ligand excluded by PLIPCL.52: 3 residues within 4Å:- Chain C: G.83, W.86
- Chain E: S.329
Ligand excluded by PLIPCL.53: 4 residues within 4Å:- Chain E: R.542, Y.543
- Chain G: R.109, E.112
Ligand excluded by PLIPCL.54: 4 residues within 4Å:- Chain E: Q.596, S.631, A.632, H.634
Ligand excluded by PLIPCL.75: 2 residues within 4Å:- Chain A: P.403
- Chain G: Q.117
Ligand excluded by PLIPCL.76: 3 residues within 4Å:- Chain A: G.83, W.86
- Chain G: S.329
Ligand excluded by PLIPCL.77: 4 residues within 4Å:- Chain E: R.109, E.112
- Chain G: R.542, Y.543
Ligand excluded by PLIPCL.78: 4 residues within 4Å:- Chain G: Q.596, S.631, A.632, H.634
Ligand excluded by PLIP- 56 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.7: 6 residues within 4Å:- Chain A: E.137, D.138, N.139, T.140, N.199, L.203
Ligand excluded by PLIPEDO.8: 5 residues within 4Å:- Chain A: Y.187, H.224, D.227, E.551, V.552
Ligand excluded by PLIPEDO.9: 5 residues within 4Å:- Chain A: K.401, S.425, S.426, D.427
- Ligands: EDO.10
Ligand excluded by PLIPEDO.10: 4 residues within 4Å:- Chain A: L.323, K.401, D.427
- Ligands: EDO.9
Ligand excluded by PLIPEDO.11: 3 residues within 4Å:- Chain A: F.517, H.518, Q.519
Ligand excluded by PLIPEDO.12: 3 residues within 4Å:- Chain A: D.170, E.186, K.192
Ligand excluded by PLIPEDO.13: 4 residues within 4Å:- Chain A: F.48, T.88, W.160, Q.271
Ligand excluded by PLIPEDO.14: 4 residues within 4Å:- Chain A: H.151
- Chain C: T.637, R.639
- Ligands: PGE.21
Ligand excluded by PLIPEDO.15: 11 residues within 4Å:- Chain A: L.119, G.122, A.123, L.127, P.128, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.16: 9 residues within 4Å:- Chain A: W.194, D.227, R.228, L.230, E.232, S.484, H.518, L.520, T.554
Ligand excluded by PLIPEDO.17: 5 residues within 4Å:- Chain A: D.27, R.162, E.215, I.238, T.275
Ligand excluded by PLIPEDO.18: 1 residues within 4Å:- Chain C: D.501
Ligand excluded by PLIPEDO.22: 5 residues within 4Å:- Chain A: N.278, S.281
- Chain B: K.129, Y.130, E.131
Ligand excluded by PLIPEDO.23: 4 residues within 4Å:- Chain B: D.93, S.137, T.138, C.180
Ligand excluded by PLIPEDO.31: 6 residues within 4Å:- Chain C: E.137, D.138, N.139, T.140, N.199, L.203
Ligand excluded by PLIPEDO.32: 5 residues within 4Å:- Chain C: Y.187, H.224, D.227, E.551, V.552
Ligand excluded by PLIPEDO.33: 5 residues within 4Å:- Chain C: K.401, S.425, S.426, D.427
- Ligands: EDO.34
Ligand excluded by PLIPEDO.34: 4 residues within 4Å:- Chain C: L.323, K.401, D.427
- Ligands: EDO.33
Ligand excluded by PLIPEDO.35: 3 residues within 4Å:- Chain C: F.517, H.518, Q.519
Ligand excluded by PLIPEDO.36: 3 residues within 4Å:- Chain C: D.170, E.186, K.192
Ligand excluded by PLIPEDO.37: 4 residues within 4Å:- Chain C: F.48, T.88, W.160, Q.271
Ligand excluded by PLIPEDO.38: 4 residues within 4Å:- Chain A: T.637, R.639
- Chain C: H.151
- Ligands: PGE.45
Ligand excluded by PLIPEDO.39: 11 residues within 4Å:- Chain C: L.119, G.122, A.123, L.127, P.128, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.40: 9 residues within 4Å:- Chain C: W.194, D.227, R.228, L.230, E.232, S.484, H.518, L.520, T.554
Ligand excluded by PLIPEDO.41: 5 residues within 4Å:- Chain C: D.27, R.162, E.215, I.238, T.275
Ligand excluded by PLIPEDO.42: 1 residues within 4Å:- Chain A: D.501
Ligand excluded by PLIPEDO.46: 5 residues within 4Å:- Chain C: N.278, S.281
- Chain D: K.129, Y.130, E.131
Ligand excluded by PLIPEDO.47: 4 residues within 4Å:- Chain D: D.93, S.137, T.138, C.180
Ligand excluded by PLIPEDO.55: 6 residues within 4Å:- Chain E: E.137, D.138, N.139, T.140, N.199, L.203
Ligand excluded by PLIPEDO.56: 5 residues within 4Å:- Chain E: Y.187, H.224, D.227, E.551, V.552
Ligand excluded by PLIPEDO.57: 5 residues within 4Å:- Chain E: K.401, S.425, S.426, D.427
- Ligands: EDO.58
Ligand excluded by PLIPEDO.58: 4 residues within 4Å:- Chain E: L.323, K.401, D.427
- Ligands: EDO.57
Ligand excluded by PLIPEDO.59: 3 residues within 4Å:- Chain E: F.517, H.518, Q.519
Ligand excluded by PLIPEDO.60: 3 residues within 4Å:- Chain E: D.170, E.186, K.192
Ligand excluded by PLIPEDO.61: 4 residues within 4Å:- Chain E: F.48, T.88, W.160, Q.271
Ligand excluded by PLIPEDO.62: 4 residues within 4Å:- Chain E: H.151
- Chain G: T.637, R.639
- Ligands: PGE.69
Ligand excluded by PLIPEDO.63: 11 residues within 4Å:- Chain E: L.119, G.122, A.123, L.127, P.128, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.64: 9 residues within 4Å:- Chain E: W.194, D.227, R.228, L.230, E.232, S.484, H.518, L.520, T.554
Ligand excluded by PLIPEDO.65: 5 residues within 4Å:- Chain E: D.27, R.162, E.215, I.238, T.275
Ligand excluded by PLIPEDO.66: 1 residues within 4Å:- Chain G: D.501
Ligand excluded by PLIPEDO.70: 5 residues within 4Å:- Chain E: N.278, S.281
- Chain F: K.129, Y.130, E.131
Ligand excluded by PLIPEDO.71: 4 residues within 4Å:- Chain F: D.93, S.137, T.138, C.180
Ligand excluded by PLIPEDO.79: 6 residues within 4Å:- Chain G: E.137, D.138, N.139, T.140, N.199, L.203
Ligand excluded by PLIPEDO.80: 5 residues within 4Å:- Chain G: Y.187, H.224, D.227, E.551, V.552
Ligand excluded by PLIPEDO.81: 5 residues within 4Å:- Chain G: K.401, S.425, S.426, D.427
- Ligands: EDO.82
Ligand excluded by PLIPEDO.82: 4 residues within 4Å:- Chain G: L.323, K.401, D.427
- Ligands: EDO.81
Ligand excluded by PLIPEDO.83: 3 residues within 4Å:- Chain G: F.517, H.518, Q.519
Ligand excluded by PLIPEDO.84: 3 residues within 4Å:- Chain G: D.170, E.186, K.192
Ligand excluded by PLIPEDO.85: 4 residues within 4Å:- Chain G: F.48, T.88, W.160, Q.271
Ligand excluded by PLIPEDO.86: 4 residues within 4Å:- Chain E: T.637, R.639
- Chain G: H.151
- Ligands: PGE.93
Ligand excluded by PLIPEDO.87: 11 residues within 4Å:- Chain G: L.119, G.122, A.123, L.127, P.128, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.88: 9 residues within 4Å:- Chain G: W.194, D.227, R.228, L.230, E.232, S.484, H.518, L.520, T.554
Ligand excluded by PLIPEDO.89: 5 residues within 4Å:- Chain G: D.27, R.162, E.215, I.238, T.275
Ligand excluded by PLIPEDO.90: 1 residues within 4Å:- Chain E: D.501
Ligand excluded by PLIPEDO.94: 5 residues within 4Å:- Chain G: N.278, S.281
- Chain H: K.129, Y.130, E.131
Ligand excluded by PLIPEDO.95: 4 residues within 4Å:- Chain H: D.93, S.137, T.138, C.180
Ligand excluded by PLIP- 12 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
PEG.19: 7 residues within 4Å:- Chain A: P.233, K.235, L.268, E.269, K.487, H.515, N.516
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:K.235, A:E.269, A:H.515, A:N.516
PEG.20: 3 residues within 4Å:- Chain A: N.178, A.179, P.180
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:N.178, A:P.180
PEG.24: 9 residues within 4Å:- Chain B: N.198, R.199, I.200, Q.213, G.215, C.216, G.220, Y.221, F.238
5 PLIP interactions:5 interactions with chain B- Hydrogen bonds: B:I.200, B:I.200, B:Q.213, B:C.216, B:Y.221
PEG.43: 7 residues within 4Å:- Chain C: P.233, K.235, L.268, E.269, K.487, H.515, N.516
4 PLIP interactions:4 interactions with chain C- Hydrogen bonds: C:K.235, C:E.269, C:H.515, C:N.516
PEG.44: 3 residues within 4Å:- Chain C: N.178, A.179, P.180
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:N.178, C:P.180
PEG.48: 9 residues within 4Å:- Chain D: N.198, R.199, I.200, Q.213, G.215, C.216, G.220, Y.221, F.238
5 PLIP interactions:5 interactions with chain D- Hydrogen bonds: D:I.200, D:I.200, D:Q.213, D:C.216, D:Y.221
PEG.67: 7 residues within 4Å:- Chain E: P.233, K.235, L.268, E.269, K.487, H.515, N.516
3 PLIP interactions:3 interactions with chain E- Hydrogen bonds: E:K.235, E:E.269, E:N.516
PEG.68: 3 residues within 4Å:- Chain E: N.178, A.179, P.180
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:N.178, E:P.180
PEG.72: 9 residues within 4Å:- Chain F: N.198, R.199, I.200, Q.213, G.215, C.216, G.220, Y.221, F.238
5 PLIP interactions:5 interactions with chain F- Hydrogen bonds: F:I.200, F:I.200, F:Q.213, F:C.216, F:Y.221
PEG.91: 7 residues within 4Å:- Chain G: P.233, K.235, L.268, E.269, K.487, H.515, N.516
3 PLIP interactions:3 interactions with chain G- Hydrogen bonds: G:K.235, G:E.269, G:N.516
PEG.92: 3 residues within 4Å:- Chain G: N.178, A.179, P.180
2 PLIP interactions:2 interactions with chain G- Hydrogen bonds: G:N.178, G:P.180
PEG.96: 9 residues within 4Å:- Chain H: N.198, R.199, I.200, Q.213, G.215, C.216, G.220, Y.221, F.238
5 PLIP interactions:5 interactions with chain H- Hydrogen bonds: H:I.200, H:I.200, H:Q.213, H:C.216, H:Y.221
- 4 x PGE: TRIETHYLENE GLYCOL(Non-functional Binders)
PGE.21: 7 residues within 4Å:- Chain A: I.150, H.151, S.207, K.208, R.209, R.493
- Ligands: EDO.14
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:Y.206, A:K.208
PGE.45: 7 residues within 4Å:- Chain C: I.150, H.151, S.207, K.208, R.209, R.493
- Ligands: EDO.38
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:Y.206, C:K.208
PGE.69: 7 residues within 4Å:- Chain E: I.150, H.151, S.207, K.208, R.209, R.493
- Ligands: EDO.62
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:Y.206, E:K.208
PGE.93: 7 residues within 4Å:- Chain G: I.150, H.151, S.207, K.208, R.209, R.493
- Ligands: EDO.86
2 PLIP interactions:2 interactions with chain G- Hydrogen bonds: G:Y.206, G:K.208
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, K.M. et al., Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion. J.Med.Chem. (2025)
- Release Date
- 2025-03-12
- Peptides
- Protein arginine N-methyltransferase 5: ACEG
Methylosome protein 50: BDFH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AG
AB
BD
BF
BH
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.75 Å
- Oligo State
- hetero-4-4-mer
- Ligands
- 4 x MTA: 5'-DEOXY-5'-METHYLTHIOADENOSINE(Non-covalent)
- 4 x 01: N-(6-amino-5-cyclopropylpyridin-3-yl)-2-[(2R,5S)-2-(1,3-benzothiazol-5-yl)-5-methylpiperidin-1-yl]-2-oxoacetamide
- 16 x CL: CHLORIDE ION(Non-functional Binders)
- 56 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 12 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- 4 x PGE: TRIETHYLENE GLYCOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, K.M. et al., Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion. J.Med.Chem. (2025)
- Release Date
- 2025-03-12
- Peptides
- Protein arginine N-methyltransferase 5: ACEG
Methylosome protein 50: BDFH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AG
AB
BD
BF
BH
B